ArticleCancers2024

Co-Occurring Infections in Cancer Patients Treated with Checkpoint Inhibitors Significantly Increase the Risk of Immune-Related Adverse Events.

Siranuysh Grabska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.